A double-blind, placebo controlled evaluation of the efficacy, safety and tolerability of BEMA [BioErodible MucoAdhesive] fentanyl in the treatment of breakthrough pain in cancer subjects

Trial Profile

A double-blind, placebo controlled evaluation of the efficacy, safety and tolerability of BEMA [BioErodible MucoAdhesive] fentanyl in the treatment of breakthrough pain in cancer subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Nov 2009

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors BioDelivery Sciences International
  • Most Recent Events

    • 25 Nov 2009 Full and final results available in Annals of Oncology, published in advance online.
    • 03 Jun 2008 Results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology.
    • 09 May 2008 Results presented at the American Pain Society Annual Meeting held in May 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top